Kevin M. Biglan, M.D., M.P.H.

Contact Information

Phone Numbers

Appointment: (585) 341-7500

Administrative: (585) 275-7430

Fax: (585) 276-1870

A member of the University of Rochester Medical Faculty Group

An Accountable Health Partner

Not Accepting New Patients

Locations

919 Westfall Rd
Clinton Crossings Bldg C, Suite 220
Rochester, NY 14618

Patient Care Setting

Neurology

Biography

Professional Background

Telemedicine: (585) 275-7430
Dr. Kevin Biglan is a Professor of Neurology and the Associate Chair for Clinical Research in the Department of Neurology and the Center for Human Experimental Therapeutics at the University of Rochester School of Medicine and Dentistry in Rochester, New York. He also serves as Director of the National Parkinson Foundation Center of Excellence and Director of the Huntington Disease Society of America Center of Excellence at the University of Rochester. He is fellowship trained in movement disorders and provides comprehensive services to individuals with Parkinson's disease, Huntington's disease, tremor, dystonia and other movement disorders. He also provides botulinum toxin injections for the treatment of dystonia and related conditions.
Dr. Biglan has been actively involved in the development of telemedicine for the provision of care in patients with Parkinson disease and for identifying disease modifying therapy in Parkinson's disease and Huntington's disease. He has been at the forefront of establishing the feasibility of telemedicine in Parkinson disease and Huntington disease, the expansion of its use for clinical care, and the validation of clinical trial outcomes assessed via telemedicine. He conducts weekly movement disorders clinics via telemedicine at various spoke sites throughout New York.

Research

Dr. Biglan is actively involved in clinical trials aimed at identifying therapies that slow progression of Parkinson disease and Huntington disease and in designing trials and identifying therapies aimed at delaying onset of disease in Huntington disease. He has served as the PI/co-PI, Steering Committee member or Medical Monitor on over 13 clinical trials. He was the co-PI on the design and successful conduct of the NINDS funded Phase 2 study of Coenzyme Q10 in premanifest Huntington's disease (PREQUEL) and the Phase 2 study of isradipine in early Parkinson disease (STEADY-PD) and is currently the PI of an NINDS sponsored Phase 3 clinical trial of isradipine in Parkinson's disease (STEADY-PDIII).
Dr. Biglan's current research interests focus on identifying clinical phenotypes in pre-manifest Huntington's disease, identifying disease modifying therapies in Huntington's disease and Parkinson's disease and enhancing the delivery of care to patients with chronic neurodegenerative disorders.

Credentials

Education

1996
MD | Jefferson Medical College

2004
MSPH | University of Rochester School of Medicine/Dentistry

Post-doctoral Training & Residency

07/01/1997 - 06/30/2000
Residency in Neurology at Thomas Jefferson University Hospital

06/24/1996 - 06/23/1997
Internship in Internal Medicine at Lankenau Hospital

Awards

1988-1992 Walton Academic Scholar, Scholarship awarded to the top 10% of matriculating students 1991, 1992 Deans Achievement Award, Award given to junior and senior students for academic excellence 1992 Cyrus E. Beekey Memorial Award, Award to a graduating senior for excellence in biology. 1996 Arthur Krieger Memorial Prize in Neurology, Award to the senior medical student exhibiting excellence in neurology 2000 Alpha Omega Alpha, Medical honor society. 2000 American Academy of Neurology Resident Scholarship, Scholarship awarded to residents exhibiting dedication to teaching 2002,2004 NIH Clinical Research Loan Repayment Award, A competitive award for clinical researchers wishing to pursue a career in academic medicine

Publications

Journal Articles

7/2016
Dorsey ER, Achey MA, Beck CA, Beran DB, Biglan KM, Boyd CM, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Ziman N, Aldred J, Carter J, Jimenez-Shahed J, Hunter C, Spindler M, Mari Z, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Bull MT, Mejia NI, Bwala G, Nance M, Shih L, Anderson L, Singer C, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Cooper J, Webb S, Dhall R, Hassan A, Weis D, DeMello S, Riggare SS, Wicks P, Smith J, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W. "National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers." Telemedicine journal and e-health : the official journal of the American Telemedicine Association.. 2016 Jul; 22(7):590-8. Epub 2016 Feb 17.

6/2016
Abdolahi A, Bull MT, Darwin KC, Venkataraman V, Grana MJ, Dorsey ER, Biglan KM. "A feasibility study of conducting the Montreal Cognitive Assessment remotely in individuals with movement disorders." Health informatics journal.. 2016 Jun; 22(2):304-11. Epub 2014 Nov 11.

1/5/2016
Achey MA, Beck CA, Beran DB, Boyd CM, Schmidt PN, Willis AW, Riggare SS, Simone RB, Biglan KM, Dorsey ER. "Erratum To: Virtual house calls for Parkinson disease (Connect.Parkinson): study protocol for a randomized, controlled trial." Trials.. 2016 Jan 5; 17:7. Epub 2016 Jan 05.

VIEW ALL PUBLICATIONS

Videos

Care at Home: Using Telemedicine to Provide Specialty Care to Patients with Parkinson Disease

Telemedicine Program Expands Reach of Care for Parkinson's Patients

Telemedicine and Parkinson disease: Improving Care and Clinical Research